This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
24 Nov 2011

Aeterna Zentaris & Hikma Ink Pact for Anti-cancer Compound

Hikma Pharmaceuticals will be responsible for the registration and commercialization of perifosine in the Middle East and North Africa region.

Aeterna Zentaris Inc. and Hikma Pharmaceuticals PLC announced Wednesday an exclusive commercialization and licensing agreement for the registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for the MENA (Middle East and North Africa) region.

 

Perifosine, a novel oral Akt inhibitor, is currently in two Phase 3 programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe.

 

Under the terms of the agreement, Aeterna Zentaris is entitled to receive an upfront payment and additional payments upon achieving certain pre-established milestones in the aggregate of $2 million. Furthermore, Aeterna Zentaris will be supplying perifosine to Hikma Pharmaceuticals on a cost-plus-basis and is entitled to receiv

Related News